RDD Blog » antibodies

R&D Directions Insider

Archive for the ‘ antibodies ’ Category

Benlysta nod should benefit remaining lupus prospects

Thursday, March 10th, 2011

FDA'sÂ approval of Benlysta is indeed an historic moment for lupus patients, a community that has waited 50 years for a new treatment. The milestone, however, may have even bigger ramifications going forward. The door for additional â€“ and perhaps more effective â€“ new drugs for the autoimmune disorder has suddenly ...

Posted in antibodies, clinical trials, drug discovery | No Comments »

Wave of momentum for cancer immunotherapies

Friday, June 4th, 2010

Since the landmark approval of Provenge in late April for prostate cancer, much has been made of the significant buzz created for similar cancer immunotherapies (see stories here and here) that stimulate a patientâ€™s immune system to recognize, attack, and kill tumor cells. Clinical data for a new wave of ...

Posted in antibodies, cancer, clinical trials | No Comments »

Tool addresses biologic registration limits

Friday, May 7th, 2010

Scientific software company Accelrys Inc. recently unveiled the worldâ€™s first multi-entity, production-ready biologics registration system. Developed from a three-year collaboration withÂ drugmakers including Abbott and Merck & Co., the data tool is designed to helpÂ companies overcome the historically difficult IT challenges associated with registering and defining complex biological materials. Accelrys' database ...

Posted in antibodies, drug discovery | No Comments »

Lupus drought: 50 years and counting

Thursday, October 8th, 2009

In this monthâ€™s issue of R&D Directions, we examine the 10 most active areas of therapeutic research, and also highlight some promising therapies for diseases in these categories. One condition researchers are particularly hesitant to lump into that â€œpromisingâ€ group is lupus â€“ and who could blame them? There have ...

Posted in Uncategorized, antibodies, clinical trials | 1 Comment »

Old MacDonald’s Pharma: Part 3

Friday, March 6th, 2009

Goats, llamas, and now chickens According to FierceBiotech, Symphogen and Origen Therapeutics are teaming up to develop a transgenic chicken that can produce recombinant human antibodies against cancer, infectious diseases, and autoimmune diseases. The chickens will be used as a live breeding ground for more complex antibody development, which is believed ...

Posted in animals, antibodies, cancer, infectious diseases, transgenics | No Comments »

Old MacDonald’s Pharma: Part 2

Wednesday, February 18th, 2009

Goats are not the only animals being used to develop new drugs. As The Wall Street JournalÂ reported on Tuesday, llamas are being used to discover treatments for diseases such as rheumatoid arthritis, cancer, and Alzheimerâ€™s disease. These pack animals and their relatives- camels and alpacas, naturally create very small antibodies ...

Posted in animals, antibodies, cancer | 1 Comment »

©2012 UBM Canon